EARLY PRESCRIPTION OF INHALATION CORTICOSTEROID IN BRONCHIAL ASTHMA
https://doi.org/10.21518/2079-701X-2017-18-32-38
Abstract
The article is devoted to the concept of early treatment of patients with intermittent and slight course of bronchial asthma with the use of fixed combinations of inhaled corticosteroids and long-acting beta2-agonists. It describes the basic pathophysiological and molecular mechanisms of this therapy, and the synergy of its components and the local anti-inflammatory effects. Considerable attention is paid to the justification of different strategies for the prescription of steroid-containing combinations as initial therapy: regular prescription of fixed doses, use of a single inhaler for maintenance and symptomatic therapy, including ICS for patients with intermittent and mild BA, abandonment of regular therapy and use of combinations only for therapy on demand. It is emphasized that the basis for the application of such a strategy is low adherence to regular ICS therapy in patients with rare symptoms and undesirability of complete withdrawal of low dose ICS in patients with the light course of the disease because of the high risk of exacerbations. Current evidence suggests that the concept of early prescription of combinations on demand allows combining symptomatic and anti-inflammatory therapy as part of the start of treatment of patients with mild bronchial asthma.
About the Authors
Z. R. Aisanov
Pirogov Russian National Research Medical Institute
Russian Federation
Russian Federation
MD, Prof.
E. N. Kalmanova
Pirogov Russian National Research Medical Institute
Russian Federation
Russian Federation
O. Y. Stulova
Pirogov Russian National Research Medical Institute
Russian Federation
Russian Federation
References
1. Papi A, Caramori G, Adcock IM, Barnes PJ. Rescue treatment in asthma: more than as-needed bronchodilation. Chest, 2009, 135: 1628-1633.
2. Papi A, Canonica G, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E et al. Rescue use of beclomethasone and albuterol in as a single inhaler for mild asthma. N Engl J Med, 2007, 356: 2040-2052.
3. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med, 2007, 356(20): 2040-2052. doi: 10.1056/ NEJMoa063861.
4. Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT ran-domized controlled trial. JAMA, 2012, 308(10): 987-997. doi: 10. 1001/2012.jama.10893.
5. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet, 2011, 377: 650-657.
6. Haahtela T, Tamminen K, Malmberg LP, Zetterstrom O, Karjalainen J, Yla-Outinen H et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J, 2006, 28(4): 748-755. doi: 10.1183/09031936.06.00128005.
7. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet, 2006, 368(9537): 744-753. doi: 10.1016/S0140-6736(06)69284-2.
8. Papi A, Caramori G, Adcock IM, Barnes PJ. Rescue treatment in asthma. More than as-needed bronchodilation. Chest, 2009, 135(6): 1628-1633. doi: 10. 1378/chest.08-2536.
9. Beasley R, Weatherall M, Shirtcliffe P, Hancox R, Reddel HK. Combination corticosteroid/ beta-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol, 2014, 133(1): 39-41. doi:
10. 1016/j. jaci.2013.10.053.
11. Beasley R, Roche W, Roberts J, Holgate S. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis, 1989, 139: 806-817.
12. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet, 2003, 361: 1071-1076.
13. Reddel HK, Taylor DR, Bateman ED, Boulet L-P, Boushey HA, Busse WW et al. An official American Thoracic Society/European Respiratory Society Statement: asthma control and exacerbations: standardizing endpoints for clinical trials and clinical practice. Am J Respir Crit Care Med, 2009, 180: 59-99.
14. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treatment asthma. N Engl J Med, 2011, 364: 2473-2475.
15. O’Byrne P, J FitzGerald M, Zhong N, Bateman E, Barnes P, Keen C, Almqvist G, Pemberton K, Jorup C, Ivanov S, Reddel H. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials. Trials, 2017 Jan 10, 18(1): 1-13.
Review
For citations:
Aisanov ZR, Kalmanova EN, Stulova OY. EARLY PRESCRIPTION OF INHALATION CORTICOSTEROID IN BRONCHIAL ASTHMA. Meditsinskiy sovet = Medical Council. 2017;(18):32-38. (In Russ.) https://doi.org/10.21518/2079-701X-2017-18-32-38
Views:
766
Email this article 